ODAC Slams Spectrum for Massaging Data From Two Bladder Cancer Trials

A brief consult with an undergraduate earning a B or above in Statistics 101 might have acquainted Spectrum Pharmaceuticals executives with all the science that would have saved them from a devastating encounter with an FDA advisory committee.